Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFCIKN)

Drug Name

Polivy Drug Info

Synonyms

Polatuzumab vedotin-piiq

Indication

Disease Entry	ICD 11	Status	REF
Mantle cell lymphoma	2A85.5	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting B-cell-specific glycoprotein B29 (CD79B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Polatuzumab vedotin	DMF6Y0L	Diffuse large B-cell lymphoma	2A81	Approved	[3]
RG7596	DMVXGU0	Haematological malignancy	2B33.Y	Phase 2	[4]
DCDS-4501A	DMQRCX5	Diffuse large B-cell lymphoma	2A81	Phase 2	[5]
MGD010	DMA368V	Autoimmune disease	4A40-4A45	Phase 1	[6]
CD79-targeted immunotoxins	DMWP63C	Non-hodgkin lymphoma	2B33.5	Investigative	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-cell-specific glycoprotein B29 (CD79B)	TTBN5I7	CD79B_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04659044) Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma. U.S. National Institutes of Health.
2	Polatuzumab Vedotin: First Global Approval. Drugs. 2019 Sep;79(13):1467-1475.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2852).
5	Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development. Mar Drugs. 2014 January; 12(1): 255-278.
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)